Canada· CA-DIN-02318261
REBIF
A interferon beta-1a product containing interferon beta-1a, registered in Canada by EMD SERONO, A DIVISION OF EMD INC., CANADA. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Interferon beta-1a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB07 (interferon beta-1a), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Interferon beta-1a · ATC L03AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of interferon beta-1a costs, country by country.
Normalised to the WHO defined daily dose (4.3 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Interferon beta-1a · price per daily dose (4.3 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$13.13
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- INTERFERON BETA-1A
- Manufacturer
- EMD SERONO, A DIVISION OF EMD INC., CANADA
- Country
- Canada (CA)
- ATC code
- L03AB07
- ATC class
- Interferon beta-1a
- Defined daily dose
- 4.3 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
347 interactions on record for interferon beta-1a.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Interferon beta-1a · interactions on record
347 records
- 15 severe
- 332 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- ClotrimazoleA01AB18moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Interferon beta-1a in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAVONEXBiogen Netherlands B.V., Badhoevedorp
- United KingdomAvonex 30microgram powder and solvent for solution for injection vialsDowelhurst Ltd
- FinlandAvonexBiogen Netherlands B.V.
- BelgiumAvonex 30 µgBiogen Netherlands
- IrelandAVONEX 30 micrograms/0.5 ml solution for injection.Biogen Netherlands B.V.
- SwedenAvonex 30 mikrogram Pulver och vätska till injektionsvätska, lösningBiogen Netherlands B.V.
- SwitzerlandAvonex
- FranceAVONEX 30 microgrammes/0,5 ml, solution injectableBIOGEN NETHERLANDS (PAYS-BAS)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Avonex, Rebif
- Liechtenstein · Avonex, Rebif
- Norway · Avonex, Rebif
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cab828fb-1de7-4324-9fde-661b4007e852 GET /v1/drugs/cab828fb-1de7-4324-9fde-661b4007e852?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02318261",
"form": "SOLUTION",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L03AB07",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "80377",
"strengths": [
"132 MCG"
],
"ahfs_class": null,
"substances": [
"INTERFERON BETA-1A"
],
"product_categorization": null
}See everything about interferon beta-1a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.